Investing.com -- Shares of Apellis Pharmaceuticals (NASDAQ: APLS) fell 8.9% in premarket trading following news that the FDA accepted a revised supplemental application from competitor Astellas Pharma ...
周五,加拿大皇家银行资本市场 (RBC Capital Markets)对Polar Capital Holdings (POLR:LN)股票启动跟踪,给予"跑赢大市"评级,目标价为6.00英镑。该公司分析师指出,预计这家资产管理公司将重新实现净资金流入,这将推动其增长超过板块平均水平,并成为公司股票重新估值的催化剂。